References
- DiNardo CD, Ogdie A, Hexner EO, et al. Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. Leuk Lymphoma 2013;54:1235–1241.
- Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011;38:1552–1562.
- Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
- Ramadan SM, Fouad TM, Summa V, et al. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012;97:805–817.
- Bakland G, Nossent H. Acute myelogenous leukemia following etanercept therapy. Rheumatology (Oxford) 2003;42:900–901.
- FDA alert. Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). Available from: http://www.fda.gov/Drugs/DrugSafety/Postmarket Drug Safety Information for Patients and Providers/Drug Safety Information for Heathcare Professionals/ucm174474.htm
- Meyboom RH, Star K, Bate J, et al. TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf 2008;31:445–447.
- Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood 1996;88:1390–1398.
- Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999;163:5358–5366.
- La Starza R, Aventin A, Matteucci C, et al. Genomic gain at 6p21: a new cryptic molecular rearrangement in secondary myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2006;20:958–964.
- Bugelski PJ, Volk A, Walker MR, et al. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 2010;29:435–466.
- Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080–1087.
- Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121–1125.
- Saba NS, Kosseifi SG, Charaf EA, et al. Adalimumab-induced acute myelogenic leukemia. South Med J 2008;101:1261–1262.
- Min HK, Lee JH, Lee HM, et al. A case of acute myeloid leukemia after adalimumab treatment in psoriatic arthritis. J Rheum Dis 2012; 19:91–94.